Virtus ETF Advisers’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Virtus ETF Advisers’s Portfolio PRTK Stock Details PRTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-20,379	Closed	-$99K	–	407
2021 Q3	$99K	Sell	20,379 -1,068	-5%	-$5.89K	0.04%	383
2021 Q2	$146K	Buy	+21,447	New	+$173K	0.06%	394
2018 Q4	–	Sell	-42,584	Closed	-$413K	–	400
2018 Q3	$413K	Sell	42,584 -31,186	-42%	-$315K	0.04%	155
2018 Q2	$752K	Buy	73,770 +31,037	+73%	+$351K	0.66%	69
2018 Q1	$556K	Buy	42,733 +23,153	+118%	+$345K	0.48%	109
2017 Q4	$350K	Buy	19,580 +4,854	+33%	+$101K	0.44%	87
2017 Q3	$370K	Buy	14,726 +1,347	+10%	+$31.4K	0.05%	116
2017 Q2	$322K	Sell	13,379 -6,830	-34%	-$151K	0.05%	104
2017 Q1	$389K	Buy	20,209 +1,938	+11%	+$30.5K	0.07%	117
2016 Q4	$281K	Buy	+18,271	New	+$237K	0.08%	114
2016 Q2	–	Sell	-14,884	Closed	-$226K	–	154
2016 Q1	$226K	Sell	14,884 -935	-6%	-$14.3K	0.31%	70
2015 Q4	$300K	Buy	+15,819	New	+$302K	0.82%	35

Other funds holding PRTK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return

GAI

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

FIG

Fortress Investment Group New York $394M AUM 22.99% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Virtus ETF Advisers's PRTK Position: Q4 2021 in Review

Virtus ETF Advisers sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q4 2021, closing a stake of 20,379 shares — an estimated $99K sold.

Virtus ETF Advisers first reported a position in PRTK in Q4 2015 and held it in 12 quarters. The position peaked at $752K in Q2 2018. 103 funds tracked by Wall St. Rank hold PRTK as of Q4 2021.

Virtus ETF Advisers reported no remaining Paratek Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
Virtus ETF Advisers sold 20,379 Paratek Pharmaceuticals, Inc. shares in Q4 2021, an estimated $99K.
Virtus ETF Advisers first reported a position in Paratek Pharmaceuticals, Inc. in Q4 2015 and held it in 12 quarters.
Virtus ETF Advisers's Paratek Pharmaceuticals, Inc. position peaked at $752K in Q2 2018.
103 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q4 2021.

Based on Virtus ETF Advisers's 13F filing for Q4 2021, filed 14 Feb 2022.